JWCAR201 / JW (Cayman) Therap - LARVOL DELTA

JWCAR201: An anti-CD19/CD20 dual CAR-T cell therapy manufactured using a rapid and automated platform exhibits enhanced antitumor efficacy and prevents antigen escape (ASGCT 2026) - "JWCAR201 generated using a rapid and automated manufacturing platform exhibited superior antitumor activity and enhanced expansion compared with traditionally manufactured CAR-T cells. These findings support JWCAR201 as a promising dual-targeting CAR-T therapy capable of addressing antigen escape while benefiting from a fast and automated manufacturing platform."

CAR T-Cell Therapy • Clinical • IO biomarker • Oncology

Preliminary safety and efficacy of anti-CD19/CD20 bispecific CAR-T cell therapy (JWCAR201) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: Results from an ongoing phase I study (ASH 2025) - P1 | "Following lymphodepleting chemotherapy (fludarabine 25 mg/m²/day × 3 days,cyclophosphamide 250 mg/m²/day × 3 days), patients received a single intravenous infusion of JWCAR201across three dose levels using a modified continual reassessment DL1 (25×10⁶ CAR⁺ T cells), DL2(50×10⁶ CAR⁺ T cells), and DL3 (100×10⁶ CAR⁺ T cells). The dual CD19/CD20targeting strategy appears promising for overcoming resistance mechanisms observed with single-antigen CAR-T therapies. Dose escalation continues with longer follow-up to establish durability ofresponses, optimal dosing, and confirm the therapeutic potential of bispecific CAR-T cell therapy in R/R B-NHL.Clinical Trial Registration: NCT06517004"

CAR T-Cell Therapy • Clinical • P1 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • BCL2 • MYC • TP53

JW (Cayman) Therapeutics…announced that the Company presented IIT study data for JWCAR201 at the 67th American Society of Hematology Annual Meeting (HKEXnews) - "This updated data comes from a single-arm, open-label, multicenter, dose-exploration IIT study conducted in China....As of October 30, 2025, preliminary results from this study showed that the best overall response rate (ORR) reached 100% (7/7) and the complete response rate (CRR) reached 85.7% (6/7) among the seven patients. Except for one patient who withdrew from the study at D90 with partial response (PR), the remaining six patients maintained remission until D180 or longer follow-up. The median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) have not yet been reached, demonstrating significant preliminary efficacy."

P1 data • Diffuse Large B Cell Lymphoma

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: RenJi Hospital

New P1 trial • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Systemic Lupus Erythematosus

An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Fudan University

New P1 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology